Suda Pharmaceuticals Ltd SMA 50
What is the SMA 50 of Suda Pharmaceuticals Ltd?
The SMA 50 of Suda Pharmaceuticals Ltd is AUD$0 +16.67%
What is the definition of SMA 50?
SMA 50 is an average stock price from the last 50 days calculated as an unweighted mean of the previous 50 stock closing prices.
Simple moving average of 50 days for a stock is an unweighted moving average over the past 50 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
SMA 50 of companies in the Health Care sector on ASX compared to Suda Pharmaceuticals Ltd
What does Suda Pharmaceuticals Ltd do?
Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.
Companies with sma 50 similar to Suda Pharmaceuticals Ltd
- Tintina Mines has SMA 50 of CAD$0 +67.00%
- Bold Ventures has SMA 50 of CAD$0 -32.22%
- Blockmint Technologies has SMA 50 of CAD$0 +0.78%
- Olivut Resources has SMA 50 of $0 -32.32%
- Freeport Resources has SMA 50 of $0 -20.66%
- WMCH Global Investment has SMA 50 of HKD$0 -32.35%
- Suda Pharmaceuticals Ltd has SMA 50 of AUD$0 +16.67%
- Eurosport Active World has SMA 50 of $0 -130.25%
- WWPKG has SMA 50 of HKD$0 -15.13%
- Wai Hung has SMA 50 of HKD$0 -75.27%
- Gibb River Diamonds has SMA 50 of AUD$0 -11.98%
- Sassy Resources has SMA 50 of $0 +64.92%
- Orefinders Resources has SMA 50 of $0 -8.82%